Akoya Biosciences and Thermo Fisher Scientific Announce a License and Distribution Agreement to Deliver Spatial Multiomics Workflow
- None.
- None.
The strategic partnership between Akoya Biosciences and Thermo Fisher Scientific represents a significant advancement in the field of spatial biology, particularly in the context of biomarker discovery and diagnostics. The integration of Akoya's PhenoImager systems and PhenoCode reagents with Thermo Fisher's ViewRNA assays facilitates a multiomic approach to tissue analysis, which is crucial for a comprehensive understanding of complex biological processes such as tumor progression.
The collaboration is likely to enhance product offerings in the spatial biology market, potentially leading to increased adoption rates among researchers. This could result in a competitive edge for both Akoya and Thermo Fisher. From an investor's perspective, the potential for growth in this niche market is notable, especially as personalized medicine and targeted therapies continue to gain traction. However, the success of this partnership will depend on the seamless integration of technologies and the ability to demonstrate improved outcomes in biomarker discovery.
The license and distribution agreement between Akoya Biosciences and Thermo Fisher Scientific taps into the growing demand for comprehensive diagnostic tools in the healthcare sector. The ability to analyze both protein and RNA biomarkers in tissue samples using a streamlined workflow could position Akoya favorably within the diagnostics and research markets. The partnership may lead to the development of more accurate biomarker signatures, which are essential for precision medicine.
Given the current market trends towards personalized healthcare, the collaboration is well-aligned with industry demands. It is important to monitor how this agreement influences Akoya's market share and revenue growth, as well as its impact on Thermo Fisher's portfolio diversification. The long-term implications could include a shift in standard practices for biomarker analysis, potentially setting a new benchmark for competitors.
The financial implications of the partnership between Akoya Biosciences and Thermo Fisher Scientific are multifaceted. For Akoya, a NASDAQ-listed company, this agreement could lead to an increase in sales of its spatial biology solutions, potentially improving its financial performance and attractiveness to investors. Thermo Fisher's established market presence and reputation may also lend additional credibility to Akoya's offerings.
Investors should consider the possible upstream revenue generation from the sale of reagents and systems, as well as the downstream potential from diagnostic applications. The success of this collaboration could be reflected in future financial statements, with an emphasis on revenue growth and market penetration. It is essential to evaluate how this partnership aligns with the strategic goals of both companies and its potential to create shareholder value in the long-term.
The Thermo Fisher Scientific ViewRNA technology combined with Akoya’s market leading spatial biology solutions will enable rapid, whole-slide imaging of RNA and protein biomarkers
MARLBOROUGH, Mass., Jan. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc., (NASDAQ: AKYA), The Spatial Biology Company®, today announced that it has entered into a license and distribution agreement with Thermo Fisher Scientific, Inc. The agreement enables Akoya to market the combination of Akoya’s spatial biology solutions, including its PhenoImager® systems and PhenoCode™ reagents with the Thermo Fisher ViewRNA In Situ Hybridization Assays, for detection of protein and RNA biomarkers in tissue samples.
The agreement facilitates a streamlined workflow for whole-slide, multiomic imaging, where protein and RNA biomarkers play complementary roles in defining cell phenotypes and cell states, respectively, in a tissue sample. Measuring both protein and RNA analytes provides researchers with a more comprehensive understanding of tumor progression, molecules and biologics, enabling development of more accurate biomarker signatures.
The Thermo Fisher ViewRNA assays are compatible with Akoya's PhenoCode™ protein panels, which deliver industry-leading solutions for high-plex and high-throughput spatial proteomics. The aim is to offer a comprehensive suite of ready-to-use and customizable multiomic solutions, streamlining the progression of biomarker programs from discovery to diagnostics.
“We are excited to work with Thermo Fisher to combine their RNA solutions with our platforms to offer a leading multiomic solution for researchers to further advance the spatial biology field,” said Brian McKelligon, CEO, Akoya Biosciences.
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our expectations about the potential of our products and services and other matters regarding our business strategies and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
Akoya Biosciences Investor Contact:
Priyam Shah
Sr. Director, Investor Relations
investors@akoyabio.com
Akoya Biosciences Media Contact:
Christine Quern
media@akoyabio.com
